HIV-Negative Rifampicin Resistance/Multidrug-Resistant Extrapulmonary Tuberculosis in China from 2015 to 2019: A Clinical Retrospective Investigation Study from a National Tuberculosis Clinical Research Center

References

• World Health Organization. Global Tuberculosis Report 2020. Geneva: World Health Organization; 2020.
   Google Scholar
• Solovic I, Jonsson J, Korzeniewska-Koseła M, et al. Challenges in diagnosing extrapulmonary tuberculosis in the European Union, 2011. Euro Surveill. 2013;18:20432. doi:10.2807/ese.18.12.20432-en
   Google Scholar
• Wang X, Yang Z, Fu Y, et al. Insight to the epidemiology and risk factors of extrapulmonary tuberculosis in Tianjin, China during 2006–2011. PLoS One. 2014;9:e112213. doi:10.1371/journal.pone.0112213
   PubMed Web of Science ®Google Scholar
• Pang Y, An J, Shu W, et al. Epidemiology of extrapulmonary tuberculosis among inpatients, China, 2008–2017. Emerg Infect Dis. 2019;25:457–464. doi:10.3201/eid2503.180572
   PubMed Web of Science ®Google Scholar
• Sandgren A, Hollo V, van der Werf MJ. Extrapulmonary tuberculosis in the European Union and European Economic Area, 2002 to 2011. Euro Surveill. 2013;18:20431. doi:10.2807/ese.18.12.20431-en
   PubMedGoogle Scholar
• Kohli M, Schiller I, Dendukuri N, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2021;1:e34.
   Google Scholar
• Huo F, Luo J, Shi J, et al. A 10-year comparative analysis shows that increasing prevalence of Rifampin-resistant Mycobacterium tuberculosis in China is associated with the transmission of strains harboring compensatory mutations. Antimicrob Agents Chemother. 2018;62(4):e02303–e2317. doi:10.1128/AAC.02303-17
   Web of Science ®Google Scholar
• World Health Organization. Global Tuberculosis Report. Geneva: World Health Organization; 2017.
   Google Scholar
• Keikha M, Karbalaei M. High resolution melting assay as a reliable method for diagnosing drug-resistant TB cases: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):989. doi:10.1186/s12879-021-06708-1
   Web of Science ®Google Scholar
• Hayward SE, Rustage K, Nellums LB, et al. Extrapulmonary tuberculosis among migrants in Europe, 1995 to 2017 – science Direct. Clin Microbiol Infect. 2020;27:1347.e1–1347.e7. doi:10.1016/j.cmi.2020.12.006
   Web of Science ®Google Scholar
• Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR. Epidemiology of extrapulmonary tuberculosis in the United States, 1993–2006. Clin Infect Dis. 2009;49:1350–1357. doi:10.1086/605559
   PubMed Web of Science ®Google Scholar
• World Health Organization. Extensively DR tuberculosis (XDR.TB): recommendations for prevention and control. Wkly Epidemiol Rec. 2006;81:430–432.
   Google Scholar
• Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993;341(8846):647–650. doi:10.1016/0140-6736(93)90417-F
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Tuberculosis Report 2018. Geneva, Switzerland: World Health Organization; 2018.
   Google Scholar
• GLI model TB diagnostic algorithms. Global Laboratory Initiative; 2017. Available from: http://www.stoptb.org/wg/gli/assets/documents/GLI_algorithms.pdf. Accessed March 15, 2022.
   Google Scholar
• Wu Z, Rueda ZV, Li T, et al. Effect of the Xpert MTB/RIF on the detection of pulmonary tuberculosis cases and rifampicin resistance in Shanghai, China. BMC Infect Dis. 2020;20(1):153. doi:10.1186/s12879-020-4871-9
   Web of Science ®Google Scholar
• Sun W, Wu Z, Zhou Y, et al. A highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis: a multicenter prospective study in China. BMC Infect Dis. 2021;21(1):834. doi:10.1186/s12879-021-06553-2
   Web of Science ®Google Scholar
• World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. world health organization; 2019
   Google Scholar
• Duan H, Chen X, Li Z, et al. Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial. Clin Microbiol Infect. 2019;25(2):190–195. doi:10.1016/j.cmi.2018.07.012
   Web of Science ®Google Scholar
• Tadesse M, Abebe G, Bekele A, et al. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a diagnostic evaluation study. Clin Microbiol Infect. 2019;25:1000–1005. doi:10.1016/j.cmi.2018.12.018
   PubMed Web of Science ®Google Scholar
• Yang C, Luo T, Shen X, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. Lancet Infect Dis. 2017;17:275–284. doi:10.1016/S1473-3099(16)30418-2
   PubMed Web of Science ®Google Scholar
• Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011;377:1495–1505. doi:10.1016/S0140-6736(11)60438-8
   PubMed Web of Science ®Google Scholar
• Kohli M, Schiller I, Dendukuri N, et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database Syst Rev. 2018;8(8):CD012768. doi:10.1002/14651858.CD012768.pub2
   PubMed Web of Science ®Google Scholar
• Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 392;2018:821–834. doi:10.1016/S0140-6736(18)31644-1
   PubMed Web of Science ®Google Scholar
• Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2012;42(1):156–168. doi:10.1183/09031936.00134712
   Web of Science ®Google Scholar
• Zhang Z, Lu J, Wang Y, Pang Y, Zhao Y. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob Agents Chemother. 2014;58(1):364–369. doi:10.1128/AAC.01228-13
   PubMed Web of Science ®Google Scholar
• Pang Y, Lu J, Huo F, et al. Prevalence and treatment outcome of extensively drug-resistant tuberculosis plus additional drug resistance from the national clinical center for tuberculosis in China: a five-year review. J Infect. 2017;75(5):433–440. doi:10.1016/j.jinf.2017.08.005
   PubMed Web of Science ®Google Scholar